Cardiac Safety of Imatinib for the Treatment of Covid-19: Results from a Randomized, Double Blind, Placebo-Controlled Trial

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	American journal of respiratory and critical care medicine
Volume	205
Publication status	Published - 1 May 2022

Cite this

@article{882ee4deafce4abdaf5c43e6cf0ca5e3,

title = "Cardiac Safety of Imatinib for the Treatment of Covid-19: Results from a Randomized, Double Blind, Placebo-Controlled Trial",

author = "E. Duijvelaar and A. Vanhove and Schippers, {J. R.} and Smeele, {P. J.} and {de Man}, {F. S.} and Pinto, {Y. M.} and Bogaard, {H. J.}",

year = "2022",

month = may,

day = "1",

language = "English",

volume = "205",

journal = "American journal of respiratory and critical care medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

}

TY - JOUR

T1 - Cardiac Safety of Imatinib for the Treatment of Covid-19: Results from a Randomized, Double Blind, Placebo-Controlled Trial

AU - Duijvelaar, E.

AU - Vanhove, A.

AU - Schippers, J. R.

AU - Smeele, P. J.

AU - de Man, F. S.

AU - Pinto, Y. M.

AU - Bogaard, H. J.

PY - 2022/5/1

Y1 - 2022/5/1

M3 - Meeting Abstract

SN - 1073-449X

VL - 205

JO - American journal of respiratory and critical care medicine

JF - American journal of respiratory and critical care medicine

ER -